
Allovir Inc (KLRS) Stock Forecast & Price Target
Allovir Inc (KLRS) Analyst Ratings
Bulls say
Kalaris Therapeutics is a promising biopharmaceutical company with a strong focus on developing and commercializing therapeutics for prevalent retinal diseases, particularly wet AMD. With its novel drug, TH103, the company has demonstrated promising results in preclinical and Phase Ia studies, setting a strong foundation for potential future success. The potential for high sales in the wet AMD market, coupled with concerns about safety and efficacy of other treatments, make Kalaris Therapeutics an attractive investment opportunity.
Bears say
Kalaris Therapeutics is still in the early stages of development, and there are a few major hurdles to overcome before TH103 can be approved for commercialization. These include addressing issues with manufacturing and inflammation, gaining regulatory approval, and competing with other existing and potential treatments for wet AMD. Additionally, the company's financials show a significant decrease in revenue over the past few years, indicating potential financial struggles and a lack of success in bringing products to market. Based on these fundamental factors, it is likely that the stock of Kalaris Therapeutics will continue to underperform in the near future.
This aggregate rating is based on analysts' research of Allovir Inc and is not a guaranteed prediction by Public.com or investment advice.
Allovir Inc (KLRS) Analyst Forecast & Price Prediction
Start investing in Allovir Inc (KLRS)
Order type
Buy in
Order amount
Est. shares
0 shares